Related Experiment Video
Updated: Mar 14, 2026

Touchscreen Sustained Attention Task SAT for Rats
Published on: September 15, 2017
Statin Adherence: Does Gender Matter?
Karen M Goldstein1,2, Leah L Zullig3,4, Lori A Bastian5,6
1Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, 508 Fulton Street, Durham, NC, 27705, USA. Karen.goldstein@duke.edu.
Insights
Women face unique challenges with statin adherence, leading to cardiovascular disease (CVD) disparities. Addressing gender-specific factors is crucial for improving statin use and outcomes in women.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Health Disparities
Background:
- Cardiovascular disease (CVD) remains a leading cause of death in the USA.
- Statins have reduced cardiovascular mortality, but their benefits are not equally distributed across genders.
- Women are less likely to use statins and achieve LDL goals compared to men.
Purpose of the Study:
- To investigate gender-based differences in the provision and adherence to statin therapy.
- To identify factors contributing to statin adherence disparities between men and women.
Main Methods:
- Review of existing literature on gender differences in statin use and adherence.
- Analysis of provider and patient-level factors influencing statin adherence.
- Exploration of psychosocial and medication intolerance factors.
Main Results:
- Women exhibit lower adherence rates to statins compared to men.
- Factors contributing to non-adherence include lower awareness of CVD risk, higher statin intolerance, and caregiving responsibilities.
- Inadequate gender-specific analyses in clinical trials limit understanding.
Conclusions:
- Gender-based disparities in statin adherence are influenced by provider, psychosocial, and intolerance factors.
- Interventions to improve statin adherence must consider women's specific challenges, including age at CVD risk onset and caregiving roles.
- Addressing these disparities is essential for equitable CVD prevention and treatment outcomes.
Purpose Of Review:
Cardiovascular disease (CVD) continues to be the leading cause of death for men and women in the USA. Statins have contributed significantly to noted declines in cardiovascular-related mortality in the last decade; however, the benefit of statins is inequitable across genders. Women continue to be less likely to take statins and to meet target LDL goals than men. As a possible contributing factor to this disparity, we explore the evidence for gender-based differences in provision of, and adherence to statins.
Recent Findings:
Compared with men, women are less likely to adhere to statins. Potential reasons for this gender difference in use of statins can be observed across all phases of adherence including both intentional and unintentional non-adherence. Notable gender-specific contributing factors for statin non-adherence include decreased provider and patient awareness of CVD risk among women, higher risk of statin intolerance among women, and competing demands associated with family caregiving responsibilities. Similar to limitations in the broader CVD literature, there is inadequate inclusion of gender-specific analyses in statin-related trials. Gender-based disparities in statin adherence can be linked to both provider level, psychosocial, and medication intolerance factors. Interventions designed to improve statin adherence should take gender-specific challenges into consideration such as women being older at the time of increased CVD risk, higher rates of statin intolerance, and potentially greater caregiving responsibilities.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Antihypertensive Drugs: Direct Renin Inhibitors
